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IMPROVING PHARMACOVIGILLANCE QUALITY MANAGEMENT SYSTEM IN THE PHARMACY AND
POISONS BOARD OF KENYA
E. Apiyo 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4

ABSTRACT
The purpose of this study was to explore ways of improving the pharmacovigilance quality system employed by
the Pharmacy and Poisons Board of Kenya. The Pharmacy and Poisons Board of Kenya employs a hybrid system
of pharmacovigilance that utilizes an online system of reporting pharmacovigilance incidences and a physical
system, where a yellow book is physically filled by the healthcare worker and sent to the Pharmacy and Poisons
Board for onward processing. This system, even though it has been relatively effective compared to other systems
employed in Africa, has one major flaw. It is a slow and delayed system that captures the data much later after
the fact and the agency will always be behind the curve in controlling the adverse incidents and events. This
means that the incidences might continue to arise or go out of control. This project attempts to develop a system
that would be more proactive in the collection of pharmacovigilance data and more predictive of pharmacovigilance
incidences. The pharmacovigilance system should have the capacity to detect and analyze subtle changes in
reporting frequencies and in patterns of clinical symptoms and signs that are reported as suspected adverse drug
reactions. The method involved carrying out a thorough literature review of the latest trends in pharmacovigilance
employed by different regulatory agencies across the world, especially the more stringent regulatory authorities.
A review of the system employed by the Pharmacy and Poisons Board of Kenya was also done.
Pharmacovigilance data, both primary and secondary, were collected and reviewed. Media reports on adverse
drug reactions and poor-quality medicines over the period were also collected and reviewed. An appropriate
predictive pharmacovigilance tool was also researched and identified. It was found that the Pharmacy and Poisons
Board had a robust system of collecting historical pharmacovigilance data both from the healthcare workers and
the general public. However, a more responsive data collection and evaluation system is proposed that will help
the agency achieve its pharmacovigilance objectives. On analysis of the data it was found that just above half of
all the product complaints, about 55%, involved poor quality medicines; 15% poor performance, 13% presentation,
8% adverse drug reactions, 7% market authorization, 2% expired drugs and 1% adulteration complaints. A
regulatory pharmacovigilance prioritization tool was identified, employing a risk impact analysis was proposed for
regulatory action.
Keywords: pharmacovigilance, poor quality medicines,adverse drug reactions, counterfeit medicines,risk
mangement.
1. INTRODUCTION
The project involved the strengthening of the quality
systems for the pharmacovigilance in the Pharmacy
and Poisons Board of Kenya. The system proposed a
data driven system that that would be more proactive
in the collection of pharmacovigilance data and more
predictive of pharmacovigilance incidences. The
Pharmacy and Poisons Board of Kenya employed a
hybrid system of pharmacovigilance that utilized an
online system of reporting and a physical system

where a yellow book was physically filled by the
healthcare worker and sent to the Pharmacy and
Poisons Board for onward processing. The previous
system was slow and not quite effective in meeting
the challenges of a modern pharmacovigilance
system. There was poor coordination between the
different departments in the Pharmacy and Poisons
Board that were meant to use and act on this
pharmacovigilance data to ensure safety and efficacy
of registered medicines in the Kenyan market. These
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departments were the Medicines and Registration
department,
the
GMP
department,
the
Pharmacovigilance department and the Import/Export
department. However, they often times worked
independently of each other and no real time data was
shared
among
them.For
example
the
Pharmacovigillance department might receive a
critical information that affects the quality of a product
in the market, if this information is not shared with the
Medicines and Registration department no regulatory
action related to the registration status of the product
will be taken such as deregistration or GMP
inspection of the manufacturing facility. This made
pharmacovigilance very reactive, causing a lot of back
log. The project, as a result, sought to improve the
system so that it could be more proactive than its
current reactive nature. It also looked to enhance the
coordination between the Medicines Registration
department and Pharmacovigilance department and
enhance the involvement of pharmaceutical
manufacturers
and
distributors
in
the
pharmacovigilance system.
Poor pharmacovigilance of medicines in Kenya will
result in poor health outcomes for the general public,
such as increased morbidity, poor quality of life and
reduced lifespan for the people of Kenya.
Borg et al. (2011) defined pharmacovigilance as the
science of, and activities relating to, the detection,
assessment, understanding and prevention of
adverse effects of marketed medicines; specifically,
taking action to increase product benefits and reduce
their risks. This is achieved by monitoring the use of
medicines in normal conditions of use to identify
previously unrecognized adverse effects or changes
in patterns of adverse effects.
In 2014, Thompson, Komparic and Smith noted that
once products are approved by regulatory authorities
and used by the public in the uncontrolled context, it
becomes very difficult for the responsible regulatory
bodies to ensure their safety and effectiveness. As a
result, regulation of pharmaceuticals and vaccines
moved towards an approach that considered the full
life cycle of the drug or vaccine. Therefore, new
strategies are being developed to allow faster
identification of high-risk interactions between
marketed drugs and adverse events to enable the
automated uncovering of scientific evidence behind
them. Pharmacovigilance plays an important role in
healthcare through assessment, monitoring and
discovery of interactions amongst drugs and their
effects
in
human
beings.
Post
market
pharmacovigilance complements the traditional
premarket austere drug approval process where the
National Regulatory Agencies establish guidelines for
new medicine approvals.

According to Lopes et al. (2013), pharmacovigilance
research is based on the analysis of “signals.” The
World Health Organization (WHO) defines signals as
undisclosed assertions or direct relationships
between adverse events or effects on a human
organism and a drug. To generate comprehensive
signal data sets, clinicians and researchers use
spontaneous reporting systems (SRS). Although drug
companies are required to track and manage adverse
events reported by clinicians or patients, the detection
process mostly relies on the physician’s ability to
recognize a given trait as a drug’s adverse event. This
normally results in underreporting and biased
selective reporting.
Labodie (2012) noted that counterfeit or adulterated
drugs have less therapeutic efficacy than the original
product, even when they do not result in additional
adverse reactions. However, when they do result in
adverse reactions, identification of those adverse
reactions, as a first indication of possible counterfeit
or adulterated drugs, requires a well-organized and
rigorous post market surveillance system at the
national level. The pharmacovigilance system should
have the capability to detect and analyze subtle
changes in reporting frequencies and in patterns of
clinical symptoms and signs that are reported as
suspected adverse drug reactions.
The latest trends in the pharmaceutical industry
strongly support the concepts of risk management
and see formal risk management as playing a major
role in the development of safe medicines for the
public, as well as providing a mechanism to ensure
that decisions concerning individual drug benefit and
risk are made based on scientific evidence. Safe
medicines refer to those drugs whose benefits have
been found to outweigh their risks when they are used
according to approved labeling. Risk management is
the comprehensive and proactive application of
scientifically based methodologies to identify, assess,
communicate and minimize risk throughout the life
cycle of a drug so as to establish and maintain a
favorable benefit-risk balance in patients (Bushet al.,
2005).
A key factor in the success of overall risk
management is the dialogue between industry and
regulators throughout the development, review and
marketing of the product. It is through such dialogue
that appropriate, efficient and effective risk
management strategies will be developed and
implemented. Pharmacovigilance has evolved over
time because of increased public awareness of the
potential risks of drug therapy through technology
(such as the internet), globalization of the industry and
changes in the industry. Consumers and media
houses have come to expect “risk free” medications,
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putting pressure on the regulators and industry alike
to ensure that pharmaceuticals “do no harm.”
Globalization has resulted in the need to
communicate with multiple regulatory bodies,
simultaneously, although the individual regulators
may have different perspectives and requirements. As
a result, regulators have increasingly placed greater
importance on the issue of benefit-risk balance of
pharmaceutical products, including greater focus on
recognizing and, where possible, mitigating risks.
Consequently, there is need to improve the current
passive system of post marketing surveillance, which
depends on a voluntary spontaneous reporting
system.

Board for the year 2015 in order to classify them
based on a risk-based system. The techniques and
tools utilized in the project included observations,
recordings, document reviews, expert interviews,
focused group discussions, interviews and
questionnaires. The method involved carrying out a
thorough literature review of the latest trends in
pharmacovigilance employed by different regulatory
agencies across the world, especially the more
stringent regulatory authorities. A review of the
system employed by the Pharmacy and Poisons
Board of Kenya was also done. Pharmacovigilance
data, both primary and secondary, were collected and
reviewed. Media reports on adverse drug reactions
and poor-quality medicines over the period were also
collected and reviewedThe data was then analysed
and presented in the tubular form below.

2. METHODS
The methodology involved a review of the poor quality
reports submitted to the Pharmacy and Poisons
Table 1. Summary of Pharmacovigillance data obtained from the Pharmacy and Poisons Board for the year 2015.
NO.

PRODUCT NAME

1

Aloha Liquid
200ml

2

Lamivudine
300mg &
Tenofovir
Desoproxil
Fumarate
300mg

3

Sulfran
suspension

ACTIVE INGRIEDIENTS

NATURE OF COMPLAINT

ACTION TAKEN

CLASSIFICATION

The product was found
to have turned from
reddish brown to green
and sedimented.

Asked to provide
sample from MAH for
comparison.
Complainant filled pink
form. Wrote to
manufacturer to
provide investigation
Reported on what
could have happened.

Quality

Lamivudine 300mg
& Tenofovir
Desoproxil
Fumarate 300mg

Similarity of product
with related product

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.memo
retrieved and given to
Dr. Mohammed

Presentation

Cotrimoxazole

The product had two
layers, an upper light
layer & darker layer at
the bottom-

Sent to NQCL for
analysis 09/02/2015

Quality

4

4

Morphine HCL
BP/PH.EUR
Powder

Morphine HCL BP
Powder

Once the powder is
Clarify with the
reconstituted with
reporter. Abdi to be
distilled water, it forms sent to the site.
a solution which starts
sedimenting after some
time.-

Quality

5

Heparin Sodium
Fresenius

Heparin Sodium

Four Patients had
severe reactions on
administration , ranging
from headache,
shivering, body
weakness, tremors,
erythematous wheal at
injection site. The
patients did not react to
different batch of
heparin procured
thereafter. See yellow
forms submitted.-

Wrote a letter to the
company and gave
reportt that we have,
awaiting response.

ADR

6

Sulfran
suspension

Cotrimoxazole

Black particles formed
on shaking the bottle
and observing under
sunlight-

Sent to NQCL for
analysis 09/02/2015

Quality

7

Sulfran
suspension

Cotrimoxazole

Black particles formed
on shaking the bottle
and observing under
sunlight-

Sent to NQCL for
analysis 09/02/2015

Quality

8

Sulfran
suspension

Cotrimoxazole

The bottle turned black- Sent to NQCL for
analysis 09/02/2015

Quality

9

Nevirapine
tablets, USP

Nevirapine

The packing is similar
to that of lamivudine
150mg from the same
manufactuer.

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

10

Lamivudine
tablets 150mg

Lamivudine 150mg

The drug has identical
packaging to
Nevirapine 200mg from
the same manufactuer.
Thus dispensing the
wrong drug is possible
because they are
aesthetically similar-

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

5

11

Lamivudine &
Lamivudine &
Tenofovir
Tenofovir Disoproxil
Disoproxil
Fumarate
Fumarate tablets

The product packaging
is similar to that of
lamivudine, Nevirapine,
& Stavudine tablets
from the same
manufactuer.

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

12

Efavirenz tablets Efavirenz tablets
600

The reason for the ADR
was due to change of
formulaion. EFV Mfg by
Macleods was cited as
the cause of severe
vomiting, dizziness,
headache, & body
ache, & when the old
formulation was
dispensed the client
was comfortable. This
is the EFV Mfg. by
Strides Arcolab Ltd that
the patient had been
taking without
complaint. Since then
client is doing well.

Communicated to
NASCOP asked
NASCOP to share any
information that they
have on the product
03/02/15 Fill it as an
ADR write to kisii a
response letter.

ADR

13

Curamol

Paracetamol

Solid crystal are seen
at the bottom of the
container.

Abwao to write a letter
to KEMSA see if they
have received any
complaint.

Quality

14

Cotrimoxazole

Sulfran

Tablets cracking & thus Sent to GMP ask for a
separating 30 tablets
sample
returned by client. 145
tablets had not been
issued to clients & have
some features. Total
tabs available 175
quarantined.

Quality

15

Sulfran

Sulphamethoxazole Crystalization. The non
Trimethoprim
- umiformity of the
syrup crystal seen in
the syrup.

16

Bupivacaine
Hydro in
dextrose

Not Potent spinal
blocade not achieved
after intra-thecal
administration.

Sent to NQCL for
analysis 09/02/2015

Quality

Sent to NQCL for
analysis 24/02/2015

Poor
performance

6

17

Efavirenz tablets Efavirenz tablets
600mg
600mg

Formulation change
related to difference in
Manufactuer. The othe
formulation is Mfg by
Macleods and Pt well
tolerated . My client a
male 60 yrs PSC No.
12,275-5 Km returned
drugs to clinic because
of generalised rahes
photos sent online
09/02/2015

Fill an ADR form

18

Curamol

Crystalization Solid
crystals have been
deposited on the
bottom of the container
shaking container did
not loosen or dissolve
the crystals.

Confirm source with the Quality
reporter and get
samples.

19

Methylated spirit

Appears to have an
abnormal colour,
thickness and smell

County pharmacist to
supply update.

Quality

Paracetamol

ADR

20

Tenfovir Disoproxil
Fumarate &
Lamivudine

Similar packaging color
(blue) with
Tdf/3tc/Efv/& Nvp
200mg making it
difficult to differentiate
the products.

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

21

Tenofovir
Disopiroxil/
Lamivudine/
Efavirenz

Similar packaging color
(blue) with Tdf/3tc &
Nvp 200mg making it
difficult to differentiate
the products.

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

22

Nevirapine 200mg

Similar Pack color blue
with Tdf/3tc/Efv and
Tdf/ 3tc making it
difficult to differentiate
the products.

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

23

Bactoclav-625

Amoxicillin/
Clavunate
500/125mg

Substandard

Results received from
NQCL 16/04/2015
Does not Comply

Quality

24

Bactoclav-625

Amoxicillin/
Clavunate
500/125mg

Substandard

Results received from
NQCL 16/04/2015
Does not Comply

Quality

7

25

Sulfran

Trimethoprim
40mg,
Sulphathoxazole
200mg

The formulation has
particles in it. It is even
rough on hand.

Sent to NQCL
09/02/2015

Quality

26

Efavirenz tablets Efavirenz tablets
600mgs
600mgs

The client cited change
of formulation as the
cause of the ADR.
when he took his first
dose of efavirenz
manufactured by
strides arcolab limited
he developed
generalized rashes the
following day. Patient
returned the drugs and
demanded for the old
formulation
manufactured by
macleods
pharmaceutical limited
which he had used
since 2006 safely

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

ADR

27

N/A

Fluphenazine
Deacanoate Inj. BP
1ml

The ampoule does not
contain the 1ml as
specified in package
the ampoule line of
weakness is not
adequate to enable
opening. At times the
ampoule breaks
inappropriately

To ask for samples

Quality

28

Erocin dry
suspension

Erythromycin
ethylsuccinate
125mg/5ml

The product should be
packed in boxes of 100
packs but all boxes
received had 6 packs
less.

Contact pharmacist for
more information.to
write a memo to
inspectorate.

Presentation

8

29

TDF 300Mg/3TC
300Mg

The two products very
similar packages
creating alot of
confusion when
dispensing at facility.
AT ONE TIME
3TC/TDF WAS
DISPENSED INSTEAD
OF 3TC/NVP/d4t AND
THE PATIENT HAD TO
BE CALLED TO COME
FOR THE RIGHT
MEDICATION. THIS
WAS REALIZED
BEFORE THE
PATIENT HAD USED
THE MEDICATION

Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.

Presentation

Presentation

30

Lamivudine
tablets 150mg

Lamivudine 150mg

The boxes and
Memo to be retrieved
containers are similarily and sent to drug Reg
and to be provided with
colored and designed.
a sample of the
photographs.

31

Isovent 200

Misoprostol
200mcg

There has been a
number of failed
inductions with the
product.

samples were collected Poor
on 19/03/2015 from
performance
Machakos L5 during
PMS

32

lidocaine
Injection B.P

Lidocaine
Hydrochloride B.P
1% w/v

severe adverse
reactions at injection
site upon injection
ophthalmologist
reported massive
oedema (orbital)
extending to the face in
all the patients he
administered. The
preparation contains
Benzyl alcohol as
preservative.

Is an ADR

ADR

33

Pure Soya Oil

Need to establish how
these products get into
the country.and then
check with drug reg
wether they are
listed.Then to see
wether we can enforce
a crack down.To
investigate herbmed
research group to
confirm where they are
getting these products.

MA

9

34

Mens Powder
Power

Ginseng root bilora
ginggigo tonkatail &
others

"

MA

35

B-tex Lotion

Salicylic acid ip
10% w/v denatured
spirit with 1%
acetone QS alcohol
content 80-90%

"

MA

36

Broad Spectrum
herbal chest (A)
powder

"

MA

37

Broad Spectrum
herbal chest (A)
powder

"

MA

38

Anti typhoid
Malaria Amoeba
Herbal Powder

"

MA

39

Sapat Plus
Lotion

"

MA

40

Purex Special
Body Detox

Aloe soctrina Urtic ,
neem a dloca,
garlic yellow dock,
senna & yarrow

"

MA

41

Biodopa

Methyldopa 350mg

Moulding observed on
tablets

Inform Biodeal if they
have any complaints
from the market. To
send out an e-shot to
check the magnitude of
the problem then from
the information
received we can make
a decision

Quality

42

Kinem

Imipenem &
Cilastatin for
injection USP

The powder does not
dissolve completely in
some vials.In others
once the powder
dissolves the solution
changes colour from
from yellow to dark
brown.

Njeri to Contact
Regulatory Pharmacist
of Medox to bring the
sample to come for a
meeting.

Quality

10

43

Dawaflox

Flucloxacillin

The above product
when reconstituted
forms a clear solution
with small black
particles were seen
inside reconstituted
product.

An e-shot was sent out
the company
pharmacist brought a
recall letter between
15th -25th of March
2015. Need to retrace
that letter from Kabue

Quality

44

Dawaflox

Flucloxacillin

The above product
when reconstituted
forms a clear solution
with small black
particles were seen
inside reconstituted
product.

An e-shot was sent out
the company
pharmacist brought a
recall letter between
15th -25th of March
2015. Need to retrace
that letter from Kabue

Quality

45

Normal Saline
nasal drops

Sodium Chloride
0.99% w/v

Suspected adulteration Get final investigational
the drug has a strong
report from Dennis
pungent smell similar to
organophosphate
chemicals. The Nasal
drops were
administered to the
child who developed
pin point pupils. Find
attached documents.

Adulteration

46

Neladol

Paracetamol

Brownish colouration of
some tablets in the
1000tab tin of
paracetamol

Refer to the older
investigational report
for neladol and to
contact the reporter

Quality

47

Salbumed

Salbutamol

The syrup is packaged
in transparent plastic
bottles as opposed to
the recommended
amber coloured bottles
to protect from sunlight.

Check with drug reg
what they registered
and follow up with the
company.To confirm
with George by
16/05/15

Quality

48

Alimoxycillin
Oral suspension

Alimox

Colour change.

QSE recommendations

Quality

49

Nepusolone
Forte eye drops

Prednisolone
Acetate 1.7m/v

Clouding lack of batch
No. prescence of
particulate matter in the
eye drops that has
caused clouding in
what should have been
a clear solution.

inform GMP &
Inspectorate to do a
follow up of the same
and guide them on
GMP issues.

Quality

11

50

Nepumiconazole Miconazole 1% m/v Clouding crystallisation
Eye drops BP
lack of batch No.
prescence of
particulate matter in
eye drops that has
caused clouding in
what should have been
clear cloudy &
sedimentation
observed.

inform GMP &
Inspectorate to do a
follow up of the same
and guide them on
GMP issues.

Quality

51

Nepucortisone
eye Drops

Hydrochloride base
PMCO 0.0048

Clouding. The product
showed prescence of
particulate matter
resulting in clouding
sedimentatiom &
caking.

inform GMP &
Inspectorate to do a
follow up of the same
and guide them on
GMP issues.

Quality

52

Bupivacaine in
Dextrose
injection USP

Bupivacaine HCL

Diminished potency.
The product was found
to have diminished
potency effective ness
to the extent of
requiring a repeat dose
to achieve spinal
anaesthesia.-

to check if they were
sent to the lab Miriam

Poor
performance

53

Isovent 200

Misoprostol
200mcg

Diminished
potency/effectiveness
the product
effectiveness was
found to be lower than
normal to the extent of
needing a repeat dose
to achieve
effectiveness.

same as above

Poor
performance

54

Tenolol - 50

Atenolol BP 50mg

Suspected poor quality- Checked with Drug
Reg. Its Registered
13/04/2015

Quality

55

Zycet syrup

Cetrizine
Hydrochloride B.P
5mg

Suspected poor quality

Not Registerd
13/04/2015

Quality

56

Zycet tablets

Cetrizine
Hydrochloride
tablets 10mg

Suspected poor quality

Not Registerd
13/04/2015

Quality Y

57

Enterezole

Diloxanide Furoate
B.P 250mg
Metronidazole
Benzoate BP

Suspected poor quality

Not Registerd
13/04/2015

Quality

12

58

Genatamicin
Eye/Ear drops

Gentamicin Sterile
10ml

Suspected poor quality

Checked with Drug
Reg. Its Registered
16/04/2015

Quality

59

Cipiem Tabkets

Chlorophenaramine Suspected poor quality
malelate B.P 4 mg

Checked with Drug
Reg. Not Registered
16/04/2015

Quality

60

Metronidazole
Intravenous
Infusion B.P

Suspected poor quality

Checked with Drug
Reg. Its Registered
16/04/2015

Quality

61

Biomol

Paracetamol

Some tablets had a
brownish colour

pick the previous
reports look at the
batches and make a
decision.

Quality

62

Alimox

Amoxicillin Oral
Suspension

Suspension changes
color when
reconstituted caking is
observed.

Implement QSE
recommendations

Quality

63

Alimox

Amoxicillin Oral
Suspension

Colour change from
white to yellow and
brown when
recostituted.

Implement QSE
recommendations

Quality

64

Alimox

Amoxicillin Oral
Suspension

Colour change from
white to yellow and
brown when
recostituted.

Implement QSE
recommendations

Quality

65

Alimox

Amoxicillin Oral
Suspension

Colour change from
white to yellow and
brown when
recostituted.

Implement QSE
recommendations

Quality

66

Alfree

Cetrizine
Dihydrocloride

The manufacturer
describes the tablet as
a white oval shaped
uncoated tablet on one
side and plain on the
other side for oral
administration. We
however noted that the
tablets are not white
but rather creamish
with yellow crystals.

Contact the Local
agent get info from
drug reg on what was
regeistered

Presentation

13

67

Kinem

Imipenem &
Cilastatin for
injection USP

After adding 10mL of
Normal saline as
appropriate and
shaking it vigorously,
the solution does not
mix. the powder quickly
settles at the bottom of
the bottle. ALso
another bottle received
from the ward had a
reddish color instead of
white to yellow color.

Contact the Local
agent get info from
drug reg on what was
regeistered

68

Kemoxyl

Amoxicillin

Capsules heads breaks Contact the reporter for
off and the contents
samples then get
intouch with the
spills in the container
company.confirm if it
was a government
tender or private
purchase.

Quality

69

Hemsyl Inj

Etamsylate BP 125

Colour change from
tinge to brown. only two
ampoule affected, signs
of slow leakage along
the neck/ scoreline as
evidenced by
comparatively low
volume of the content
and mould like
substances around the
necks of affected
ampoules.

Quality

70

TDF/3TC/NVP
and TDF/3TC
and NVP
Tablets

to Call the company on
27/05/2015 and ask
them to provide a
sample.

Quality

The complaint is about refer above Cristabel to Presentation
the packaging of the
follow up
TDF/3TC/EFV,
TDF/3TC and NVP
from this company.
Their outer packaging
look very identical. This
can cause serious
dispensing errors
especially in busy
hospital pharmacy
departments and where
there are trainees in the
department. they are
also very confusing to
our patients. The color
and design of the
packaging should be
changed See the
pictures attached,

14

especially the ones on
the shelves.
71

Jotomol

Paracetamol

crumbling and breaking a letter to be written to
of tablets into small
be to BENMED
particles and powder

72

Pyremol

Paracetamol
Suspension

The syrup has
Call the reporter to give Quality
unpleasant smell and
us samples.and also
the labelling is different. call Concepts africa Ltd
The same product but
the other one has faint
label

73

Salol

Salbutamol

Powdering and
crumbling

Check registration
status and ask for
samples.Biopharma to
be sent for a letter

Quality

74

Chlorist

Chlorophenaramine Powdering and
malelate B.P 4 mg crumbling

Check the registration
status and contact
syner Med.

Quality

75

Metopride

Metoclopramide
injection BP
10mg/2ml

THE AMPUOLE
NEEDS TO HAVE
CLEAR SOLUTION
FOR INJECTION BUT
THIS CONTAINS
LIGHT-BLUE
SOLUTION.
AWAITING
RECOMMENDATION
N FROM YOUR
OFFICE ON THE WAY
FORWARD BUT TGE
AMPOULE HAS BEEN
QUARANTINED FOR
THE TIMR BEING.

Ask the reporter to
send samples then we
contact the
company.Get the local
agent from Drug reg.

Quality

76

Heparovit-H

Heparin Injection

The patient
experienced shivering,
difficulty in breathing
and bronchospasms on
administration on a
dialysis patient on two
occasions

Should be reported as
an ADR Cristabel to
call to get more
information.

ADR

Quality
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77

Diclofence
Sodium

THE AMPOULES
HAVE SOME LEAKING
POINTS THAT DRAIN
GRADUALLY. SOME
AMPOULES ARE
COMPLETELY
EMPTY. THIS
HAPPENS IN AT
LEAST 20-40% OF
THE AMPS

Contact the reporter to
send samples. Find the
local distributor.to
check registration
status, confirm with the
reporter if it was
supplied by KEMSA

Quality

78

Nicardia

Nifedipine

Complaints that the
product is not reducing
blood pressure.

Contact the reporter to
send samples. Find the
local distributor.to
check registration
status, confirm with the
reporter if it was
supplied by KEMSA

Poor
performance

79

Nicardia

Nifedipine

Complaints that the
product is not reducing
blood pressure.as
required

Contact the reporter to
send samples. Find the
local distributor.to
check registration
status, confirm with the
reporter if it was
supplied by KEMSA

Poor
performance

80

Dawa-flox

Flucloxacillin

Capsules were opened
and the powder spilt.
Some other capsules
had different colours

Contact supplier &
reporter to give us
samples. Talk to Dr.
Wasike about it

Quality

81

Quinine
Quinine inj
Dihydrocholoride 600mcl/2ml
I.V

the quantitiy of the
drugs is incomplete
because of the poorly
packed ampoules.

contact the company
and refer the company
to GMP and check
GMP status and check
if it was supplied by
KEMSA

Presentation
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82

Fluphenazine
Decanoate
Injection BP 1ml

Fluphenazine
The nurses in the
Decanoate Injection psychiatric ward
BP 1ml
reported several cases
of patients that
experienced relapses
of psychosis 2 weeks
after administration of
the drug instead of 4
weeks.The nurses
carried out an
experiment where they
issued the same batch
under question to some
patients and a different
brand from another
company. Those who
were given the batch
under question
returned with psychosis
while those who got the
other brand came back
on there appointment
day after 4 weeks.

Contact the reporter for
more information, ask
them for samples
check registrations
status of what it
contains.

Poor
performance

83

Artesun 120mg

Artesunate injection full course of
artesunate injection
drug administered to 2
patients with a positive
blood smear for
malaria. the MPS after
treatment was still
positive. patients were
switched to quinine
injection and they
responded well.

Registration status
Contact them to find if
the have samples

Poor
performance

84

Oxytocin 10 i.u

Oxytocin 10 i.u

Low efficacy i.e Using
up to 4times the normal
dosages to achieve
desired results as
stored at room
temperature.

Send abwao an email
to ask him about the
outcome of the
oxytocin analysis

Poor
performance

85

Gripe Water

Sodium
Bicarbonate

White Floating particles Ask the reporter to
provide samples and
ask the manufacturer
for samples.

Quality

86

Neocuron

Pancuronium

The effects wear out
To ask the reporter for
within a very short time samples to send to
(20-25 minutes), higher NQCL
doses are required.
Anesthetists have had
to use doses as high as

Poor
performance
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18mg for an operation
of two and a half hours.
Telmsartan with
HCL

Bought Expired drugs
from Temple Stores
Pharmaceuticals on
30/05/2015

87

Unitel -H 40

88

Artemether
20mg
Lumefantrine
120mg

89

Apresoline

Hydrlazine Injection The powder for
reconstitution has
changed color from
yellow to white, the
product has caked at
the bottom of the
ampule and the
resultant powder after
intensive shaking of the
ampule is not free
flowing.

90

Parace

Paracetamol

91

Dawa flox

92

93

To liaise with
inspectorate.

After taking meds
experienced skin
rashes & difficulty
breathing feeling
exhausted.Expired drug
was given to patient
boss. After finishing the
dose the client went to
hospital after which he
was told to report to
PPB

Expired
drugs

ADR

to contact reporter to
bring sample and to
also contact
manufacturer to bring
sample

Quality

The tablets crumbles
/breaks easily into
pieces.

To registration status
and get samples from
reporter

Quality

Flucloxacillin
125mg/5ml powder
for suspension

Particular bottles of the
said batch started
caking & color change
from white to pink.

we will sample for more Quality
and sent an e-shot to
the county pharmacist

Diclofenac
Injection

Diclofenanc Inj

The drug has changed
in color i.e to pink color

To confirm registration
status and act from
there.Call the reporter
to fill a yellow form,
quarantine the product
and then hand over the
case to inspectorate

Quality

Bupivacaine
HCL dextrose
injection

Bupivacaine HCL
dextrose injection

The product does not
achieve optime levels
of anaesthesia @
therapeutic doses

Refer to same

Poor
performance
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94

Tenoretic

Sold for expired drug
from on 8th July 2015

95

Misoprostol
Tablets
KONTRAC 200

Misoprostol
200mcg

Lack of efficacy

96

Hepa

Heparine 5000iu

There is coagulation
despite increase in
dosage of the drug.

97

Ceftriaxone

Ceftrimed

Patient on treatment for Reporter to be advised
severe UTI.put on
to fill a yellow form
ceftriaxone 1gm of for
ADR form
5/7.developed itchiness
mild on day one of
treatment and was
reassured..has
developed type 1
hypersensitivity
reaction after finishing
dose ..1later.patients
has swollen
face..periorbital edema
and wheels....over the
whole body.patient has
associated intense
itchiness which results
to wheals after
scratching.

ADR

98

Aziagio

Overwhelmingly
Repugnant spicy smell,
coarse consistency and
bitter pepperminty taste
with a strong aftertaste. Induces vomiting
almost instantly even to
a normal adult.
Absolutely unpalatable
for paediatric patient

Quality

99

Ascoril
Expectorant

Salbutamol
Bromhexine
Guaiifenesin &
Menthol

Inspectorate to give an
update on this case

Expired
drugs
Poor
performance

Take to NQCL for
analysis 04/08/2015

to call the reporter ask
for sample and ask the
reporter what he
meant.

PRODUCT
Inspectorate to do
LABELLING/PACKAGE followup and provide
AND PRODUCT
samples.
COMPOSITION IS
UNREGISTERED. HAS
TERBUTALINE
SULPHATE IP 1,25MG
INSTEAD OF
SALBUTAMOL
SULPHATE BP 2MG.

Poor
performance

Presentation
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IT DOES NOT HAVE A
UNIT BOX OR PIL
100 Dolomol

Dolomol

The tablets have
changed colour to
brown

To ask for samples and Quality
to send an eshot and
get in touch with the
supplier or
manufacturer.

101 Nimodor -s

Sufadoxine 500mg
Pyrimethamine
25mg

The tablets are said on
the label to be film
coated while in actual
sense they are
uncoated. Plus there is
no literature for the
product or any other
information apart from
the sticker on the tin.
The tablets look like
any other circular tablet
with no engraving for
identification and the
description states that
its film coated while
onnchechikng they are
uncoated white circular
tablets

Get samples contact
the agent Look at the
submitted dossier on
what was suggested.

102 Dolomol

Paracetamol

Moulding

To ask for samples and Quality
to send an eshot and
get in touch with the
supplier or
manufacturer Edward
to do the eshot Mary to
follow up.

103 Hepa

Heprin Sodium BP
5000iu

The drug was found to
be in-effective. Blood
coagulation took place
during dialysis despite
it being administered in
correct doses.

To follow up with the
lab NQCL

104 Biodopa

Methyldopa 250 Mg The yellow tablets form Abwao to do an eshot
Tablets
moulds and turn to grey and find out from
in colour
KEMSA if there is a
report on the
same.Mary to contact
Biodeal

Quality

Poor
performance

Quality
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105 RHZE COM

Rifampicine,
isoniazid,
ethambutal,
pyrazinamud

The drug RHZE turned
dark brown from brown
and crumbling happen
to a whole row in a
pack. Patient complaint
in change of test, feels
as if has not taken any
medicine (different from
other similar medicine

Edward called on
Quality
23/09/2015 To ask for
samples so that we can
send them for analysis

106 Telmi 80H

Telmisattan 80mg
The medicine
Hydrochlorothiazide disintegrate/dissolves
12.5mg tablets
before swallowing

Sent to NQCL
04/08/2015

Quality

107 Cytotec

Misoprostol
200mcg

Suspected potency
issue one mother
experienced raptured
uterus and the other
one had precipitate
labour is still born birth.

To liaise with Drug reg
Dr Mbwiri and ministry
of reproductive health

Poor
performance

108 Depin E Retard

Nifedipine Retard
Tabs

Batch
No.Manufacturing date
and Expiry date of
product omitted.

write am email to
Quality
MEDS Get Kingori to
dispatch a team to
quarantine and give the
quantities and to give a
list of all the places
supplied.

109 Not Indicated

Not Indicated

The product was
packed together with
Diclofenanc tablets
50mg but not labelled

write am email to
Quality
MEDS Get Kingori to
dispatch a team to
quarantine and give the
quantities and to give a
list of all the places
supplied.

110 Cytotec

Misoprostal tablets
200mcgs

It is a follow up of the
ADR that was reported
on 31/07/2015

To contact Ministry of
Reproductive Health.

111 OXYTOCIN
INJECTION BP

OXYTOCIN

There was several
complaints from
maternity ward that the
drug failed to produce
the desire effect
(induction of uterine
contraction)

Dr. Kimathi Draft a
Poor
letter to the registrar for performance
change in storage
conditions. To liaise
with drug Reg

ADR
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112 Ferrous
Sulphate Tablets

The tablets are dull red
instead of the usual
bright red, they break in
the mouth like chalk
which is not what I am
used to. I feel dizzy
upon taking them which
is odd. Something is
just not right.

Edward contacted the
reporter and they were
to organise on how
they can collect the
samples from the
hospital

Quality

The product passes
analysis so we to Write
to the owner of the
product/agents to
explain the problem
followed by a literature
review contract experts
to analyse the product.

Poor
performance

113 Bupivit - D

Bupivacaine
Hydrochloride in
Dextrose injection

After spinal injection it
does not pick, most of
the time it fails and if
lucky it picks it gives
more hypotension than
the block intended.

114 Metropride

Metoclopramide
injection BP
10mg/2ml

The liquid in the
ampuoles have
different colors, some
colorless, some are
bluish green. This may
indicate that there is
some color change.

Quality

115 Carefenac

Diclofenanc
Sodium Inj

Ampoules not labelled.
Severe discomfort on
injection (severe pain
redness & swelling) at
the site of injection.

Presentation

116 Diclomed

Diclofenac Sodium

Packs contain
ampoules with different
colours of solution i.e
Clear yellow.

Quality

Black growths spotted
in the colourless soln
supposedly having
grown overtime
suspected to be
moulds.

Quality

117 Hartmann's Soln
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Regulatory Pharmacovigilance Prioritisation System (RPPS) refer to appendix.
A Regulatory pharmacovigillance prioritization system adopted from Seabroke et al. (2013) was developed. This
tool is prposed for adoption by the Pharmacy and Poisons Board Pharmacovigillance department. It is a risk-based
system that implements regulatory action based on a weighted system, as shown in Table 2 below.
The tool reviews different sources of pharmacovigillance information and weights them depending on their impact
on their importance. The different categories are regulatory obligations, public health implications, strength of
evidence and public perceptions. Input is the source of the pharmacovigillance data. Criteria for a positive
response in the RPPS tool indicates the severity of the adverse effect and the number of points is the weight given
to the criteria.
Table 2.
Category

Input

Criteria for a positive response in RPPS

Public health
implications

Drug/vaccine
exposure

Estimated number of patients prescribed medication in
the past

Number
of
Points
3

year in Kenya is[100,000 or the drug is newly marketed
but
with the potential for rapid uptake
Frequency of ADR

Absolute frequency of the ADR is thought to be at least
1/1,000

2

users
Health
consequences

Combined case fatality rate plus non-fatal outcome
score in Impact

4

Analysis is 0.7 or greater
Spontaneous case
reports

In total, more than 20 cases or three fatalities have
been reported

1

spontaneously in Kenya
Regulatory
obligations

Ministerial/public
health

The Cabinet Secretary of Health or Ministry of Health
has expressed concern

authority concern

about the drug or sent significant correspondence in the
last

1

12 months
Recent
parliamentary

Parliamentary questions relevant to the safety of the
drug have

questions

been posed in the last 12 months

EAC obligations

Kenya is rapporteur or reference member state for the
drug

3

Marketing
Authorisation

An application from the Marketing Authorisation Holder
has some

2

Holder application

bearing on the issue, e.g. an application to reclassify
from a
prescription-only medicine to a pharmacy-supplied
medicine

1
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Strength of
evidence

Disproportionality
measure/

An EBGMb[10 (spontaneous ADR data) and/or RR[3
(RCT or

risk estimate

epidemiological study) has been observed

Data sources

More than one data source provides positive clinical
evidence of a
hazard (e.g. spontaneous
observational study)

Public perceptions

ADR

data

plus

2

4

an

Evidence from RCT
or
meta-analysis

At least some positive evidence comes from a RCT or
metaanalysis

4

Biological plausibility

There is some biological plausibility for the ADR

2

Media attention

There has been significant media attention for the drug
in the last

3

12 months
Factors likely to
cause
public anxiety

Two or more factors in the following list are present:

4

• ADR threatens death (C5 % case fatality in
spontaneous ADR
data)
• ADR threatens vulnerable groups (e.g. children,
pregnant
women)
• ADR is generally unavoidable by taking precautions
(few clear
risk factors, no specific monitoring)
• ADR involves cancer, teratogenicity, suicidality or
major
neurological disability
• Scientific basis for ADR is poorly understood (no
known
biological plausibility)
• Experts have publicly disagreed about the existence
or scale of
the problem
• New first-in-class drug where the safety profile is not
yet
established

Public
misperceptions

Potential public misperceptions about the safety of the
drug could
be expected to cause harm through a behavior change
(e.g.
decreased vaccine uptake, abrupt discontinuation of
medicine)

Other Public
concerns

Any other indication that the matter is causing public
concern

1
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3. RESULTS AND DISCUSSION
Based on the data collected in Table 1, it was noted
that the current pharmacovigilance system utilized by
the Pharmacy and Poisons Board collected
numerous data relevant to pharmacovigilance. On
analysis of the data it was observed that just above
half of all the product complaints, approximately
55%, involved poor quality medicines, 15% on poor
performance, 13% on presentation, 8% on adverse
drug reactions, 7% market authorization, 2% expired
drugs and 1% adulteration complaints. This was
good information; however, it did not give guidance
on the next step to be carried in order to reduce or
mitigate these pharmacovigilance incidences. A new
system, Regulatory Pharmacovigilance Prioritization
System, adapted from Seabroke et al. (2013) was
proposed to be implemented to develop regulatory
action as a result of these pharmacovigilance
incidences. The tool was deemed appropriate since
it utilized a weighted risk-based system, as shown in
Table 2, to determine regulatory action. This tool took
into account, not only the current pharmacovigilance
parameters recorded by the system, but also
included public health implications such as drug
exposure, recent parliamentary questions, marketing
authorization, public anxiety and misperceptions and
other concerns, which are not captured in the current
system. The weighting of the pharmacovigilance
incidence will help the agency make decisions on
how to handle the pharmacovigillance incidences.
The higher the weight the more effort need to be put
in place to mitigate or prevent such future
occurences. This will make the system more
proactive and responsive in regulatory actions.
4. CONCLUSION
This project gives the Pharmacy and Poisons Board
a new tool that it could use to improve
pharmacovigilance of medicines in the Kenyan
market. The tool uses a risk-based system to weight
and prioritize different pharmacovigilant relevant
signals that could be used to make regulatory
decisions and actions. This system is definitely more
proactive and responsive to the needs of the public
whose safety pharmacovigilance is supposed to
protect.
5. RECOMMENDATIONS FOR NEXT STEPS
The next step would be to implement the Regulatory
Pharmacovigilance Prioritization system. Since the
system incorporates pharmacovigilance signals that
are currently not captured, such as public health
implications, public perceptions, media perceptions,
recent parliamentary questions, etc., it would be

necessary to redesign the pharmacovigilance
information collection system to take these factors
into account. The tool should be redesigned to reflect
the current needs and capabilities of the Pharmacy
and Poisons Board. The tool is in the form of a flow
chart however it can be adapted into a mobile phone
application for ease of use.
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